Etodesnitazene

  1. Home
  2. Wiki

Desnitroetonitazene
Legal status
Legal status
Identifiers
  • 2-[2-[(4-Ethoxyphenyl)methyl]benzimidazol-1-yl]-N,N-diethylethanamine
CAS Number
PubChem CID
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H29N3O
Molar mass351.494 g·mol−1
3D model (JSmol)
  • CCN(CC)CCN1C2=CC=CC=C2N=C1CC3=CC=C(C=C3)OCC
  • InChI=1S/C22H29N3O/c1-4-24(5-2)15-16-25-21-10-8-7-9-20(21)23-22(25)17-18-11-13-19(14-12-18)26-6-3/h7-14H,4-6,15-17H2,1-3H3
  • Key:BMLPNUNXHUGDOI-UHFFFAOYSA-N

Etodesnitazene (also known as desnitroetonitazene, etazen, etazene, and etazone) is a benzimidazole-derived opioid analgesic drug, which was originally developed in the late 1950s alongside etonitazene and a range of related derivatives.[1] It is many times less potent than etonitazene itself, but still 70 times more potent than morphine in animal studies. Corresponding analogues where the N,N-diethyl group is replaced by piperidine or pyrrolidine rings also retain significant activity (10 times and 20 times morphine, respectively).[2] Etodesnitazene has been sold as a designer drug,[3] first being identified in both Poland and Finland in March 2020.[4][5]

[edit]

United Kingdom

[edit]

Since 15 January 2025 it is covered by the UK's generic definition on 2-benzyl benzimidazole derived opioids[6][7] because it contains the 2-(2-benzyl-benzimidazol-1-yl)ethanamine backbone with only the following modification:[8]

  • The phenyl ring of the benzyl system is substituted by an alkoxy group containing two carbon atoms.

See also

[edit]

References

[edit]
  1. ^ Ujváry I, Christie R, Evans-Brown M, Gallegos A, Jorge R, de Morais J, Sedefov R (April 2021). "DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles". ACS Chemical Neuroscience. 12 (7): 1072–1092. doi:10.1021/acschemneuro.1c00037. PMID 33760580. S2CID 232356192.
  2. ^ Hunger A, Kebrle J, Rossi A, Hoffmann K (1960). "Benzimidazol-Derivate und verwandte Heterocyclen. II. Synthese von 1-Aminoalkyl-2-benzyl-benzimidazolen". Helvetica Chimica Acta (in German). 43 (3): 800–809. doi:10.1002/hlca.19600430323.
  3. ^ Siczek M, Zawadzki M, Siczek M, Chłopaś-Konowałek A, Szpot P (2020). "Etazene (N,N-diethyl-2-{[(4-ethoxyphenyl)methyl]-1H-benzimidazol-1-yl}-ethan-1-amine (dihydrochloride)): a novel benzimidazole opioid NPS identified in seized material: crystal structure and spectroscopic characterization". Forensic Toxicology. doi:10.1007/s11419-020-00552-9. ISSN 1860-8973.
  4. ^ Siczek M, Zawadzki M, Siczek M, Chłopaś-Konowałek A, Szpot P (January 2021). "Etazene (N,N-diethyl-2-{[(4-ethoxyphenyl)methyl]-1H-benzimidazol-1-yl}-ethan-1-amine (dihydrochloride)): a novel benzimidazole opioid NPS identified in seized material: crystal structure and spectroscopic characterization". Forensic Toxicology. 39 (1): 146–155. doi:10.1007/s11419-020-00552-9. ISSN 1860-8965.
  5. ^ "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.
  6. ^ "The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2024 and The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment) (No. 2) Regulations 2024". GOV.UK. Retrieved 2025-05-30.
  7. ^ "Britain working at pace to curb rising synthetic drugs threat". GOV.UK. Retrieved 2025-06-12.
  8. ^ "The Misuse of Drugs Regulations 2001 (2024 Order (No. 2))". Legislation.gov.uk. HM Government (UK). Retrieved 11 August 2025.